Search Results - "Lomaia, E G"

Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases by Melikyan, A L, Subortseva, I N, Gilyazitdinova, E A, Koloshejnova, T I, Pustovaya, E I, Egorova, E K, Kovrigina, A M, Sudarikov, A B, Abdullaev, A O, Lomaia, E G, Siordiya, N T, Zaritskey, A Yu, Savchenko, V G

“…A comparative evaluation of the effectiveness of different therapeutic strategies in patients with polycythemia vera (PV) and essential thrombocythemia (ET)…”
Get full text

Retrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia by Kustova, D. V., Motyko, E. V., Kirienko, A. N., Gert, T. N., Leppyanen, I. V., Bakay, M. P., Efremova, E. V., Morozova, E. V., Lomaia, E. G., Shuvaev, V. A., Sidorkevich, S. V., Martynkevich, I. S.

“…Background . Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors achieve durable optimal responses. Loss of the achieved…”
Get full text

CASC5 Gene Expression Changes Correlate with Targeted Mutations in Leukemia by Bogdanov, K. V., Merzlikina, O. V., Mirolyubova, Y. V., Girshova, L. L., Lomaia, E. G., Zaritskey, A. Y.

“…Dysfunction of genes that control mitosis and are responsible for the correct segregation of sister chromatids in anaphase is often accompanied by aneuploidy,…”
Get full text

Change of concentration of biochemical markers of dysfunction of endothelium at intake of inhibitors of tyrosinekinase of I and II generations at patients with a chronic myeloid leukemia as risk factor of development of cardiovascular complications by Naumova, K. V., Davydkin, I. L., Lomaia, E. G., Stepanova, T. Yu, Kuzmina, T. P., Zammoyeva, D. B.

“…CML), the accepting inhibitors tyrosine of kinases (TKI) I and the II generations (TKI1 and TKI2 respectively), and development of arterial hypertension…”
Get full text

Identification of oncogene mutations in leukemia patients using microchip-based PCR analysis by Bogdanov, K. V., Nikulina, T. S., Lomaia, E. G., Slyadnev, M. N., Zaritskey, A. Y.

“…At present, cytogenetic and PCR-based techniques are generally used in the diagnosis of leukemia. Due to high accuracy, specificity, and sensitivity of PCR…”
Get full text

CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTOSIS AND PRIMARY MYELOFIBROSIS DEPENDING ON JAK2 AND CALR1 MUTATION STATUS by Lisina, E. G., Siordiya, N. T., Butylin, P. A., Silyutina, A. A., Matyukhina, N. M., Senderova, O. M., Fokina, E. S., Ovsepyan, V. A., Lomaia, E. G., Zaritskiy, A. Yu

“…Introduction. JAK2V617F mutation is detected in approximately 50 % of patients with essential thrombocytosis (ET) and primary myelofibrosis (PMF). In 2013 most…”
Get full text

Quality of life, symptom profile and clinical efficacy of second-line treatment with dasatinib in patients with imatinib-resistant or -intolerant chronic myeloid leukemia: results of 2-year follow-up by Ionova, T. I., Nikitina, T. P., Lomaia, E. G., Kuchma, G. B., Machyulaytene, E. R., Usacheva, E. I., Shnaider, T. V., Rodionova, A. Yu, Kurbatova, K. A.

“…The article is focused on the results of the multicenter observational study “Quality of life and symptom profile in patients with chronic myeloid leukemia in…”
Get full text

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial by Cortes, Jorge, Apperley, Jane, Lomaia, Elza, Moiraghi, Beatriz, Undurraga Sutton, Maria, Pavlovsky, Carolina, Chuah, Charles, Sacha, Tomasz, Lipton, Jeffrey H., Schiffer, Charles A., McCloskey, James, Hochhaus, Andreas, Rousselot, Philippe, Rosti, Gianantonio, de Lavallade, Hugues, Turkina, Anna, Rojas, Christine, Arthur, Christopher Kevin, Maness, Lori, Talpaz, Moshe, Mauro, Michael, Hall, Tracey, Lu, Vickie, Srivastava, Shouryadeep, Deininger, Michael

“…In PACE (Ponatinib Ph+ ALL and CML Evaluation), a phase 2 trial of ponatinib that included patients with chronic-phase chronic myeloid leukemia (CP-CML)…”
Get full text

Chronic myeloid leukemia — before and after imatinib (First part) by E. G. Lomaia, D. V. Motorin, E. G. Romanova, A. Yu. Zaritzkiy

“…The first successful experience effective target therapy has been achieved at imatinib administration in chronic myeloid leukemia (CML) treatment. Disease…”
Get full text

Chronic myeloid leukemia — before and after imatinib (Third part) by E. G. Lomaia, M. Yu. Konopleva, E. G. Romanova, A. Yu. Zaritzkiy

“…Imatinib (IM) appearance has changed approaches to chronic myeloid leukemia (CML) therapy. Second generation tyrosine kinase inhibitors (TKI) — nilotinib and…”
Get full text

Nilotinib - new step of success in CML therapy by E. G. Lomaia, A. Y. Zaritskey

Get full text

CASC5 Gene Expression Changes Correlate with Targeted Mutations in Leukemia by Bogdanov, K V, Merzlikina, O V, Mirolyubova, Y V, Girshova, L L, Lomaia, E G, Zaritskey, A Y

“…Dysfunction of genes that control mitosis and are responsible for the correct segregation of sister chromatids in anaphase is often accompanied by aneuploidy,…”
Get more information

CML-047 Post Hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial by Deininger, Michael, Apperley, Jane, Arthur, Christopher Kevin, Chuah, Charles, Hochhaus, Andreas, de Lavallade, Hugues, Lipton, Jeffrey, Lomaia, Elza, McCloskey, James, Maness, Lori, Mauro, Michael, Moraghi, Beatriz, Pavlovsky, Carolina, Rosti, Gianantonio, Rousselot, Philippe, Sutton, Maria Undurraga, Ren, Xiaowei, Vorog, Alexander, Cortes, Jorge

“…Objectives: OPTIC (NCT02467270) is a Phase 2 trial evaluating the safety and efficacy of ponatinib in patients with CP-CML resistant to ≥2 TKIs or have a T315I…”
Get full text

Chronic myeloid leukemia — before and after imatinib (part II) by E. G. Lomaia, N. S. Lazorko, E. Salamatova, E. G. Romanova, A. Yu. Zaritzkiy

Get full text

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia by E. G. Lomaia, E. G. Romanova, E. I. Sbityakova, A. Yu. Zaritskiy

“…Current treatment options for chronic myeloid leukemia (CML) with imatinib allowed achieving long-term progression-free and overall survival and improved…”
Get full text

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia by E. G. Lomaia, E. G. Romanova, E. I. Sbityakova, A. Yu. Zaritskiy

“…Current treatment options for chronic myeloid leukemia (CML) with imatinib allowed achieving long-term progression-free and overall survival and improved…”
Get full text

Nilotinib i dazatinibv 1-y linii terapii bol'nykhkhronicheskim mieloleykozomv khronicheskoy faze by N S Lazorko, E G Lomaia, E I Sbityakova, A Yu Zaritskiy

Get full text

Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia by Zaritskiĭ, A Iu, Lomaia, E G, Vinogradova, O Iu, Druzhkova, G A, Kolosheĭnova, T I, Loria, S S, Pospelova, T I, Krylova, I V, Kruglov, S S, Kuznetsov, S V, Chelysheva, E Iu, Abakumov, E M, Sokolova, M A, Nemchenko, I S, Zakharova, E S, Goriacheva, S R, Kolosova, L Iu, Vakhrusheva, M V, Liamkina, A S, Chernova, O A, Machiulaĭtene, E R, Ivanova, V L, Udal'eva, V Iu, Shneĭder, T V, Ogorodnikova, Iu S, Zhuravlev, V S, Zakharova, A V, Martynkevich, I S, Domracheva, E V, Afanas'ev, B V, Abdulkadyrov, K M, Kovaleva, L G, Khoroshko, N D, Turkina, A G

“…To reveal prognostically significant factors affecting efficacy of glivek therapy in untreated (duration of the disease < or = 6 months) and pretreated…”
Get more information